Pharmaceutical

Biocytogen and Ona enter cancer ADC development deal

Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.

Dec 18, 2023 - 10:51
Biocytogen and Ona enter cancer ADC development deal
Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.
Read the original article

Tags:

Previous Article

Vertex secures CHMP nod for Casgevy approval in Europe

Next Article

CymaBay seeks FDA approval for primary biliary cholangitis therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers

STAT+: Here’s why there aren’t many cheap, generic vers...

Mar 19, 2023

CHMP recommends oral peanut allergy immunotherapy treatment for toddlers  

CHMP recommends oral peanut allergy immunotherapy treat...

Dec 3, 2024

STAT+: U.S. Anesthesia Partners, Welsh Carson face class action over monopoly allegations

STAT+: U.S. Anesthesia Partners, Welsh Carson face clas...

Nov 23, 2023